{
  "timestamp": "2026-02-13T00:55:27.701269+00:00",
  "runs_analyzed": [
    {
      "session_id": "evo_20260210_232904_pharmacology",
      "domain": "pharmacology",
      "question": "What mechanisms explain why low-dose lithium is neuroprotective while therapeutic-dose lithium causes nephrotoxicity, and what molecular targets determine the dose-dependent switch between cytoprotect",
      "s3_passed": false,
      "n_claims": 13
    },
    {
      "session_id": "evo_20260210_235609_pharmacology",
      "domain": "pharmacology",
      "question": "What mechanisms explain why low-dose lithium is neuroprotective while therapeutic-dose lithium causes nephrotoxicity?",
      "s3_passed": false,
      "n_claims": 9
    },
    {
      "session_id": "evo_20260211_024747_pharmacology",
      "domain": "pharmacology",
      "question": "What are the mechanisms by which chronic low-dose THC produces sustained improvements in subjective wellbeing, and how does CB1 receptor modulation interact with endocannabinoid tone to produce therap",
      "s3_passed": false,
      "n_claims": 9
    },
    {
      "session_id": "evo_20260211_024750_neuroscience",
      "domain": "neuroscience",
      "question": "What mechanisms explain the finding that low-dose THC reverses age-related cognitive decline in animal models, and does chronic CB1 activation restore neuroplasticity through BDNF, neurogenesis, or sy",
      "s3_passed": false,
      "n_claims": 7
    },
    {
      "session_id": "evo_20260211_201329_pharmacology+bioelectric",
      "domain": "pharmacology+bioelectric",
      "question": "Does circadian cycling of mitochondrial membrane potential alter the dose-response threshold at which CBD shifts from cytoprotective to cytotoxic effects via VDAC1, and what time-dependent mechanisms ",
      "s3_passed": false,
      "n_claims": 10
    },
    {
      "session_id": "evo_20260212_032819_pharmacology",
      "domain": "pharmacology",
      "question": "What determines whether VDAC1 engagement by a small molecule results in neuroprotection versus cytotoxicity? Specifically, how do cell-type-specific cofactor landscapes \u2014 including HK-II occupancy, Bc",
      "s3_passed": false,
      "n_claims": 7
    },
    {
      "session_id": "evo_20260213_004656_consciousness",
      "domain": "consciousness",
      "question": "Does the spectral decomposition of per-token Fisher Information matrices in pretrained transformers reveal discrete bonding geometries \u2014 specifically, do semantically rigid tokens (logical connectives",
      "s3_passed": false,
      "n_claims": 10
    }
  ],
  "cross_matches": [
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.7914,
      "classification": "CROSS-PROMOTED",
      "type_a": 2,
      "type_b": 0,
      "statement_a": "1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) i",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "Partial agonism at CB1 maintains receptor sensitivity by favoring G-protein coupling over \u03b2-arrestin, preventing desensitization while enhancing tonic endocannabinoid signaling.",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.7765,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3\u03b2 inhibition (IC50 1-2 mM), stabilizing \u03b2-catenin, upregulating BDNF and autophagy.",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Li+ mimics Mg2+ uncompetitively at GSK3\u03b2 active site, reducing phosphorylation of pro-apoptotic substrates proportionally to dose.",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.7187,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "The therapeutic index of lithium is fundamentally narrow because the K\u1d62 for GSK-3\u03b2 inhibition is only one to two orders of magnitude lower than the concentration that disrupts renal Na\u207a/K\u207a-ATPase func",
      "statement_b": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 w",
      "mechanism_a": "The neuroprotective ED50 is driven by GSK-3\u03b2 inhibition (K\u1d62 \u2248 1-2 mM, but effective in vivo at lower plasma levels), while the nephrotoxic TD50 is driven by disruption of ion pumps essential for renal",
      "mechanism_b": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma."
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6921,
      "classification": "CROSS-PROMOTED",
      "type_a": 2,
      "type_b": 0,
      "statement_a": "1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) i",
      "statement_b": "Aged hippocampus shows pathologically elevated GABAergic tone, such that low-dose THC (CB1 on interneurons) restores balance via disinhibition, specific to aging vs. young.",
      "mechanism_a": "Partial agonism at CB1 maintains receptor sensitivity by favoring G-protein coupling over \u03b2-arrestin, preventing desensitization while enhancing tonic endocannabinoid signaling.",
      "mechanism_b": "Aging \u2191perineuronal nets/GABA release elevates inhib tone; low THC reduces it toward youth levels without young overexcitation."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6874,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro \u22480.3 mM serum equiv., TD50>3 mM.",
      "statement_b": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 w",
      "mechanism_a": "Constrained by FDA prior; narrow window emerges from higher renal IMPase sensitivity vs. brain GSK3\u03b2.",
      "mechanism_b": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6824,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n \u2248 2\u20133), reflecting cooperative depletion of inositol pools, creating a steep threshold rather than gradual toxicity onset.",
      "statement_b": "3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stre",
      "mechanism_a": "Inositol pool depletion is nonlinear \u2014 IMPase inhibition must exceed a threshold before phosphoinositide recycling collapses, producing apparent cooperativity in the toxicity dose-response.",
      "mechanism_b": "(effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.681,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "The therapeutic index of lithium is fundamentally narrow because the K\u1d62 for GSK-3\u03b2 inhibition is only one to two orders of magnitude lower than the concentration that disrupts renal Na\u207a/K\u207a-ATPase func",
      "statement_b": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) an",
      "mechanism_a": "The neuroprotective ED50 is driven by GSK-3\u03b2 inhibition (K\u1d62 \u2248 1-2 mM, but effective in vivo at lower plasma levels), while the nephrotoxic TD50 is driven by disruption of ion pumps essential for renal",
      "mechanism_b": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6644,
      "classification": "CROSS-PROMOTED",
      "type_a": 2,
      "type_b": 0,
      "statement_a": "The therapeutic index of lithium is fundamentally narrow because the K\u1d62 for GSK-3\u03b2 inhibition is only one to two orders of magnitude lower than the concentration that disrupts renal Na\u207a/K\u207a-ATPase func",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "The neuroprotective ED50 is driven by GSK-3\u03b2 inhibition (K\u1d62 \u2248 1-2 mM, but effective in vivo at lower plasma levels), while the nephrotoxic TD50 is driven by disruption of ion pumps essential for renal",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6637,
      "classification": "INDEPENDENT REPLICATION",
      "type_a": 1,
      "type_b": 0,
      "statement_a": "3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (\u22642.5 mg/day) adds to tonic 2-AG without displacement, while high-dose THC (>10 mg/day) saturates CB1, reducing 2-AG access",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "Low-dose THC occupies CB1 without competing with 2-AG, preserving tonic signaling; high-dose THC displaces 2-AG, triggering MAGL-mediated degradation.",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6625,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "2**: Therapeutic-dose lithium (>1.0 mM serum) induces nephrotoxicity via inositol monophosphatase (IMPase) inhibition, causing inositol depletion and ER stress in renal cells, which lack the Nrf2-medi",
      "statement_b": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) an",
      "mechanism_a": ": IMPase inhibition depletes phosphatidylinositol bisphosphate (PIP\u2082), triggering ER stress (e.g., CHOP, XBP1 splicing) in renal cells; neurons mitigate this via Nrf2-driven glutathione synthesis. - *",
      "mechanism_b": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6574,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro \u22480.3 mM serum equiv., TD50>3 mM.",
      "statement_b": "Dose-discrepancy from PK-driven TI expansion: effective brain TI_GSK3 ~20-50 (ED50_plasma 0.2 mM / TD50_plasma 10 mM), renal TI_ENaC ~2-3 due to 5\u00d7 accumulation factor.",
      "mechanism_a": "Constrained by FDA prior; narrow window emerges from higher renal IMPase sensitivity vs. brain GSK3\u03b2.",
      "mechanism_b": "Accumulation factor (AF_kidney/AF_brain ~5) \u00d7 target Ki ratio shrinks apparent plasma TI below prior minimum=10."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6489,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 2,
      "type_b": 3,
      "statement_a": "3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligome",
      "statement_b": "1:** The neuroprotection-to-cytotoxicity transition follows a cooperative oligomerization threshold: apoptosis requires \u22654 adjacent cofactor-free VDAC1 monomers, so cytotoxicity probability scales as ",
      "mechanism_a": "Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.",
      "mechanism_b": "Cofactors sterically shield VDAC1 lateral interfaces; ligand-mediated displacement at high occupancy increases f_free past the percolation threshold for oligomer nucleation, releasing cytochrome c."
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6482,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) i",
      "statement_b": "2:** Chronic low-dose THC restores plasticity predominantly via rapid synaptic remodeling (increased spine density/complexity), with BDNF as a necessary mediator and neurogenesis as a delayed, seconda",
      "mechanism_a": "Partial agonism at CB1 maintains receptor sensitivity by favoring G-protein coupling over \u03b2-arrestin, preventing desensitization while enhancing tonic endocannabinoid signaling.",
      "mechanism_b": "Sustained disinhibition (lowering GABA tone from a pathologically high baseline toward EC50 ~15 uM efficacy) lowers LTP threshold, enabling spine formation/stabilization driven by CREB-BDNF-TrkB signa"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6468,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "The therapeutic index of lithium is fundamentally narrow because the K\u1d62 for GSK-3\u03b2 inhibition is only one to two orders of magnitude lower than the concentration that disrupts renal Na\u207a/K\u207a-ATPase func",
      "statement_b": "The functional therapeutic window is created by differential bioaccumulation: brain intracellular [Li\u207a] equilibrates near serum levels (~1x), while renal collecting duct cells concentrate Li\u207a to >5x s",
      "mechanism_a": "The neuroprotective ED50 is driven by GSK-3\u03b2 inhibition (K\u1d62 \u2248 1-2 mM, but effective in vivo at lower plasma levels), while the nephrotoxic TD50 is driven by disruption of ion pumps essential for renal",
      "mechanism_b": "Neurons maintain ionic homeostasis via efficient transporters, whereas renal principal cells are specialized for Na\u207a reabsorption, a system Li\u207a hijacks for entry but not for efficient exit, leading to"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6447,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 trafficking and osmoregulation.",
      "statement_b": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) an",
      "mechanism_a": "Chronic IMPase block reduces IP1 hydrolysis, depleting inositol for phosphoinositide synthesis needed in proximal tubule cells under hyperosmotic stress.",
      "mechanism_b": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6446,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 1,
      "statement_a": "The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n \u2248 2\u20133), reflecting cooperative depletion of inositol pools, creating a steep threshold rather than gradual toxicity onset.",
      "statement_b": "Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events ",
      "mechanism_a": "Inositol pool depletion is nonlinear \u2014 IMPase inhibition must exceed a threshold before phosphoinositide recycling collapses, producing apparent cooperativity in the toxicity dose-response.",
      "mechanism_b": "Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manne"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6365,
      "classification": "INDEPENDENT REPLICATION",
      "type_a": 1,
      "type_b": 0,
      "statement_a": "(Supporting SINGULAR thread) Neuronal BDNF/TrkB signaling is potentiated by low-dose lithium via GSK-3\u03b2 inhibition and CREB activation, providing a robust compensatory pro-survival signal absent in re",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Lithium-enhanced BDNF/TrkB signaling activates PI3K/Akt and ERK pathways, which converge on mTOR and Bcl-2 to suppress apoptosis and enhance autophagy, buffering against mild metabolic stress.",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6365,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 1,
      "type_b": 3,
      "statement_a": "Cytoprotective CBD (EC50 2-3.7 \u03bcM via TRPV1/2) dominates daytime (hyperpolarized \u03c8 closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1.",
      "statement_b": "The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentration range (~0.5x Kd \u2248 5.5 \u00b5M) is an order of mag",
      "mechanism_a": "Low-dose CBD modulates Ca2+/metabolite flux protectively; VDAC1 closure at -180 mV requires >Kd CBD for forced oligomerization.",
      "mechanism_b": "The separation between the on-target VDAC1 affinity and off-target CYP3A4 inhibition affinity is insufficient to meet the minimum therapeutic index of 10."
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6341,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "THC \u03b2-arrestin recruitment EC50 > G-protein EC50 (bias factor ~3-5), so low occupancy (<30%) yields therapeutic cAMP inhibition without GRK2/\u03b2arr downregulation.",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "Biased agonism preserves receptor recycling (t1/2~hours) by limiting phosphorylation at low efficacy occupancy.",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6271,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "Dose-switch via tissue context: neurons activate Nrf2/BDNF (low-dose induced) buffering mild inositol depletion; renal cells lack robust compensation, amplifying toxicity.",
      "statement_b": "The functional therapeutic window is created by differential bioaccumulation: brain intracellular [Li\u207a] equilibrates near serum levels (~1x), while renal collecting duct cells concentrate Li\u207a to >5x s",
      "mechanism_a": "Low Li triggers adaptive Nrf2 antioxidants and BDNF/TrkB survival in neurons (singular thread validated by lit.), absent in proximal tubules leading to ROS/fibrosis at same dose.",
      "mechanism_b": "Neurons maintain ionic homeostasis via efficient transporters, whereas renal principal cells are specialized for Na\u207a reabsorption, a system Li\u207a hijacks for entry but not for efficient exit, leading to"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6246,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 1,
      "statement_a": "Hill coefficient n=1 for both effects governs hyperbolic switch; intracellular [Li] window [1-10]uM for peak protection before toxicity onset.",
      "statement_b": "Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events ",
      "mechanism_a": "Non-cooperative binding to single sites (GSK3/IMPase); renal accumulation via transporters widens effective window gap.",
      "mechanism_b": "Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manne"
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6246,
      "classification": "CROSS-PROMOTED",
      "type_a": 1,
      "type_b": 2,
      "statement_a": "Cytoprotective CBD (EC50 2-3.7 \u03bcM via TRPV1/2) dominates daytime (hyperpolarized \u03c8 closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1.",
      "statement_b": "3:** The biphasic response is mechanistically distinct at low vs. high occupancy: sub-Kd CBD (<5 \u00b5M) allosterically enhances HK-II\u2013VDAC1 affinity (positive cooperativity at N-terminal helix), while su",
      "mechanism_a": "Low-dose CBD modulates Ca2+/metabolite flux protectively; VDAC1 closure at -180 mV requires >Kd CBD for forced oligomerization.",
      "mechanism_b": "CBD binds a lipid-facing pocket near the VDAC1 N-terminal helix; low occupancy stabilizes helix-in conformation (HK-II-compatible), high occupancy forces helix-out (HK-II-incompatible, oligomerization"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6226,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 trafficking and osmoregulation.",
      "statement_b": "3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stre",
      "mechanism_a": "Chronic IMPase block reduces IP1 hydrolysis, depleting inositol for phosphoinositide synthesis needed in proximal tubule cells under hyperosmotic stress.",
      "mechanism_b": "(effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6194,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3\u03b2 inhibition (IC50 1-2 mM), stabilizing \u03b2-catenin, upregulating BDNF and autophagy.",
      "statement_b": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 w",
      "mechanism_a": "Li+ mimics Mg2+ uncompetitively at GSK3\u03b2 active site, reducing phosphorylation of pro-apoptotic substrates proportionally to dose.",
      "mechanism_b": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6176,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 1,
      "type_b": 3,
      "statement_a": "Circadian depolarized \u0394\u03a8m (-165 mV nighttime) lowers CBD cytotoxic IC50 3-5x (to 3-5 \u03bcM from 15 \u03bcM daytime), enabling sub-Kd (11 \u03bcM) toxicity via VDAC1.",
      "statement_b": "The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentration range (~0.5x Kd \u2248 5.5 \u00b5M) is an order of mag",
      "mechanism_a": "Depolarized \u0394\u03a8m favors VDAC1 open state (P_open >80%), enhancing CBD binding cooperativity (Hill n>1.5) and oligomerization for cyt c release.",
      "mechanism_b": "The separation between the on-target VDAC1 affinity and off-target CYP3A4 inhibition affinity is insufficient to meet the minimum therapeutic index of 10."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6171,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "The dose-dependent switch is governed by the biphasic modulation of inositol monophosphatase (IMPase) and GSK-3\u03b2; low-dose inhibition is submaximal (~20-40%) and activates pro-survival PI3K/Akt and Nr",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Partial IMPase/GSK-3\u03b2 inhibition at low [Li+] (\u22640.5 mM) causes mild, non-toxic stress that triggers adaptive transcription via Nrf2 and CREB, whereas high [Li+] (\u22651 mM) causes severe phosphoinositide ",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6096,
      "classification": "CROSS-MATCH",
      "type_a": 2,
      "type_b": 2,
      "statement_a": "3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligome",
      "statement_b": "3:** The biphasic response is mechanistically distinct at low vs. high occupancy: sub-Kd CBD (<5 \u00b5M) allosterically enhances HK-II\u2013VDAC1 affinity (positive cooperativity at N-terminal helix), while su",
      "mechanism_a": "Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.",
      "mechanism_b": "CBD binds a lipid-facing pocket near the VDAC1 N-terminal helix; low occupancy stabilizes helix-in conformation (HK-II-compatible), high occupancy forces helix-out (HK-II-incompatible, oligomerization"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6035,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 2,
      "type_b": 3,
      "statement_a": "Dose-switch via tissue context: neurons activate Nrf2/BDNF (low-dose induced) buffering mild inositol depletion; renal cells lack robust compensation, amplifying toxicity.",
      "statement_b": "The primary mechanism for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding",
      "mechanism_a": "Low Li triggers adaptive Nrf2 antioxidants and BDNF/TrkB survival in neurons (singular thread validated by lit.), absent in proximal tubules leading to ROS/fibrosis at same dose.",
      "mechanism_b": "for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding the Ki for IMPase inh"
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6023,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int \u00d7 fractional_occupancy. For CB1, k_recycle \u2248 0.02 min\u207b\u00b9, k_int \u2248 0.",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "CB1 internalization follows agonist-driven \u03b2-arrestin-dependent endocytosis; at low occupancy, the internalization flux (k_int \u00d7 occupied_receptors) remains below the constitutive recycling/synthesis ",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6013,
      "classification": "CROSS-PROMOTED",
      "type_a": 2,
      "type_b": 1,
      "statement_a": "3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligome",
      "statement_b": "The cytotoxic threshold for VDAC1 ligands scales as Kd \u00d7 (1 + [HK-II]/Ki_HK) \u00d7 (Bcl-xL/Bax) \u00d7 (1 + [tubulin]/Ki_tub), yielding >10\u00d7 higher thresholds in neurons (TI > 10) vs. cancer cells (TI < 5).",
      "mechanism_a": "Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.",
      "mechanism_b": "HK-II, Bcl-xL, and tubulin act as competitive inhibitors of ligand-induced oligomerization by sequestering VDAC1 monomers; their combined buffering capacity sets the free VDAC1 fraction."
    }
  ],
  "cross_validated_singulars": [
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.7765,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3\u03b2 inhibition (IC50 1-2 mM), stabilizing \u03b2-catenin, upregulating BDNF and autophagy.",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Li+ mimics Mg2+ uncompetitively at GSK3\u03b2 active site, reducing phosphorylation of pro-apoptotic substrates proportionally to dose.",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6874,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro \u22480.3 mM serum equiv., TD50>3 mM.",
      "statement_b": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 w",
      "mechanism_a": "Constrained by FDA prior; narrow window emerges from higher renal IMPase sensitivity vs. brain GSK3\u03b2.",
      "mechanism_b": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6824,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n \u2248 2\u20133), reflecting cooperative depletion of inositol pools, creating a steep threshold rather than gradual toxicity onset.",
      "statement_b": "3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stre",
      "mechanism_a": "Inositol pool depletion is nonlinear \u2014 IMPase inhibition must exceed a threshold before phosphoinositide recycling collapses, producing apparent cooperativity in the toxicity dose-response.",
      "mechanism_b": "(effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6625,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "2**: Therapeutic-dose lithium (>1.0 mM serum) induces nephrotoxicity via inositol monophosphatase (IMPase) inhibition, causing inositol depletion and ER stress in renal cells, which lack the Nrf2-medi",
      "statement_b": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) an",
      "mechanism_a": ": IMPase inhibition depletes phosphatidylinositol bisphosphate (PIP\u2082), triggering ER stress (e.g., CHOP, XBP1 splicing) in renal cells; neurons mitigate this via Nrf2-driven glutathione synthesis. - *",
      "mechanism_b": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6574,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "Therapeutic index TD50_nephro/ED50_neuro >10, with ED50_neuro \u22480.3 mM serum equiv., TD50>3 mM.",
      "statement_b": "Dose-discrepancy from PK-driven TI expansion: effective brain TI_GSK3 ~20-50 (ED50_plasma 0.2 mM / TD50_plasma 10 mM), renal TI_ENaC ~2-3 due to 5\u00d7 accumulation factor.",
      "mechanism_a": "Constrained by FDA prior; narrow window emerges from higher renal IMPase sensitivity vs. brain GSK3\u03b2.",
      "mechanism_b": "Accumulation factor (AF_kidney/AF_brain ~5) \u00d7 target Ki ratio shrinks apparent plasma TI below prior minimum=10."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6489,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 2,
      "type_b": 3,
      "statement_a": "3:** The cytotoxic transition occurs NOT at depolarized \u0394\u03a8m but at **hyperpolarized** \u0394\u03a8m (~-180 mV), where VDAC1 partial closure promotes oligomerization; CBD at \u22655 \u03bcM stabilizes closed-state oligome",
      "statement_b": "1:** The neuroprotection-to-cytotoxicity transition follows a cooperative oligomerization threshold: apoptosis requires \u22654 adjacent cofactor-free VDAC1 monomers, so cytotoxicity probability scales as ",
      "mechanism_a": "Closed VDAC1 exposes oligomerization interfaces (\u03b2-strands 1,2,19); CBD's hydrophobic intercalation between monomers stabilizes hexameric pores large enough for cytochrome c (~12 kDa) passage.",
      "mechanism_b": "Cofactors sterically shield VDAC1 lateral interfaces; ligand-mediated displacement at high occupancy increases f_free past the percolation threshold for oligomer nucleation, releasing cytochrome c."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6447,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 trafficking and osmoregulation.",
      "statement_b": "2:** *Nephrotoxicity arises from intracellular [Li\u207a] trapping in renal principal cells (2\u201320\u00d7 plasma levels) due to ENaC-mediated uptake and poor Na\u207a/K\u207a-ATPase efflux, exceeding IMPase Ki (~0.8 mM) an",
      "mechanism_a": "Chronic IMPase block reduces IP1 hydrolysis, depleting inositol for phosphoinositide synthesis needed in proximal tubule cells under hyperosmotic stress.",
      "mechanism_b": "ENaC admits Li\u207a with P_Li/P_Na \u22651, but basolateral Na\u207a/K\u207a-ATPase extrudes Li\u207a ~10\u00d7 slower than Na\u207a, causing accumulation to 2\u201316 mM at 0.8 mM plasma, triggering IMPase inhibition and lysosomal stress."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6446,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 1,
      "statement_a": "The dose-response curve for nephrotoxicity follows a Hill coefficient >1 (n \u2248 2\u20133), reflecting cooperative depletion of inositol pools, creating a steep threshold rather than gradual toxicity onset.",
      "statement_b": "Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events ",
      "mechanism_a": "Inositol pool depletion is nonlinear \u2014 IMPase inhibition must exceed a threshold before phosphoinositide recycling collapses, producing apparent cooperativity in the toxicity dose-response.",
      "mechanism_b": "Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manne"
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6365,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 1,
      "type_b": 3,
      "statement_a": "Cytoprotective CBD (EC50 2-3.7 \u03bcM via TRPV1/2) dominates daytime (hyperpolarized \u03c8 closes VDAC1, blocking cytotoxicity); nighttime flip via open VDAC1.",
      "statement_b": "The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentration range (~0.5x Kd \u2248 5.5 \u00b5M) is an order of mag",
      "mechanism_a": "Low-dose CBD modulates Ca2+/metabolite flux protectively; VDAC1 closure at -180 mV requires >Kd CBD for forced oligomerization.",
      "mechanism_b": "The separation between the on-target VDAC1 affinity and off-target CYP3A4 inhibition affinity is insufficient to meet the minimum therapeutic index of 10."
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6341,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "THC \u03b2-arrestin recruitment EC50 > G-protein EC50 (bias factor ~3-5), so low occupancy (<30%) yields therapeutic cAMP inhibition without GRK2/\u03b2arr downregulation.",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "Biased agonism preserves receptor recycling (t1/2~hours) by limiting phosphorylation at low efficacy occupancy.",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6246,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 1,
      "statement_a": "Hill coefficient n=1 for both effects governs hyperbolic switch; intracellular [Li] window [1-10]uM for peak protection before toxicity onset.",
      "statement_b": "Nephrotoxicity exhibits a sharp, non-linear dose-response (Hill coefficient > 1.5) because intracellular Li\u207a accumulation past a critical threshold (~2-3 mM) triggers cooperative, catastrophic events ",
      "mechanism_a": "Non-cooperative binding to single sites (GSK3/IMPase); renal accumulation via transporters widens effective window gap.",
      "mechanism_b": "Beyond simple enzyme inhibition, supraphysiological intracellular cation levels trigger stress responses that function as all-or-none switches, amplifying cellular damage in a highly cooperative manne"
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6226,
      "classification": "CONVERGENT SINGULAR",
      "type_a": 3,
      "type_b": 3,
      "statement_a": "Nephrotoxicity at therapeutic dose (0.8-1.5 mM) driven by IMPase inhibition (IC50 0.3-0.6 mM), causing myo-inositol depletion critical for renal AQP2 trafficking and osmoregulation.",
      "statement_b": "3:** Nephrotoxicity involves a threshold/cooperative mechanism (effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stre",
      "mechanism_a": "Chronic IMPase block reduces IP1 hydrolysis, depleting inositol for phosphoinositide synthesis needed in proximal tubule cells under hyperosmotic stress.",
      "mechanism_b": "(effective Hill n \u2248 1.5\u20132.5) because damage requires simultaneous IMPase inhibition (Ki ~0.8 mM), disrupted AQP2 trafficking, and ER stress \u2014 each independently insufficient."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6194,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 2,
      "statement_a": "Lithium neuroprotection at low dose (<0.5 mM) primarily via partial GSK3\u03b2 inhibition (IC50 1-2 mM), stabilizing \u03b2-catenin, upregulating BDNF and autophagy.",
      "statement_b": "4:** The clinical therapeutic index (~2\u20133) dramatically underestimates the *brain-specific* TI because brain [Li\u207a] at toxic plasma levels (~1.5 mM) remains ~1\u20131.8 mM \u2014 still below direct GSK-3\u03b2 Ki \u2014 w",
      "mechanism_a": "Li+ mimics Mg2+ uncompetitively at GSK3\u03b2 active site, reducing phosphorylation of pro-apoptotic substrates proportionally to dose.",
      "mechanism_b": "The organ-specific TI for brain neuroprotection vs. renal toxicity is ~10\u201320\u00d7 when indexed to intracellular concentrations rather than plasma."
    },
    {
      "run_a": "evo_20260211_201329_pharmacology+bioelectric",
      "run_b": "evo_20260212_032819_pharmacology",
      "cosine": 0.6176,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 1,
      "type_b": 3,
      "statement_a": "Circadian depolarized \u0394\u03a8m (-165 mV nighttime) lowers CBD cytotoxic IC50 3-5x (to 3-5 \u03bcM from 15 \u03bcM daytime), enabling sub-Kd (11 \u03bcM) toxicity via VDAC1.",
      "statement_b": "The therapeutic window for a neuroprotective VDAC1 ligand like CBD is practically non-existent due to off-target effects. The neuroprotective concentration range (~0.5x Kd \u2248 5.5 \u00b5M) is an order of mag",
      "mechanism_a": "Depolarized \u0394\u03a8m favors VDAC1 open state (P_open >80%), enhancing CBD binding cooperativity (Hill n>1.5) and oligomerization for cyt c release.",
      "mechanism_b": "The separation between the on-target VDAC1 affinity and off-target CYP3A4 inhibition affinity is insufficient to meet the minimum therapeutic index of 10."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6171,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "The dose-dependent switch is governed by the biphasic modulation of inositol monophosphatase (IMPase) and GSK-3\u03b2; low-dose inhibition is submaximal (~20-40%) and activates pro-survival PI3K/Akt and Nr",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Partial IMPase/GSK-3\u03b2 inhibition at low [Li+] (\u22640.5 mM) causes mild, non-toxic stress that triggers adaptive transcription via Nrf2 and CREB, whereas high [Li+] (\u22651 mM) causes severe phosphoinositide ",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6035,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 2,
      "type_b": 3,
      "statement_a": "Dose-switch via tissue context: neurons activate Nrf2/BDNF (low-dose induced) buffering mild inositol depletion; renal cells lack robust compensation, amplifying toxicity.",
      "statement_b": "The primary mechanism for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding",
      "mechanism_a": "Low Li triggers adaptive Nrf2 antioxidants and BDNF/TrkB survival in neurons (singular thread validated by lit.), absent in proximal tubules leading to ROS/fibrosis at same dose.",
      "mechanism_b": "for the dose-discrepancy is differential intracellular accumulation: kidney principal cells achieve 3-5x plasma [Li\u207a] (therapeutic plasma 0.8 mM \u2192 ~3 mM intracellular), exceeding the Ki for IMPase inh"
    },
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6023,
      "classification": "CROSS-VALIDATED SINGULAR",
      "type_a": 3,
      "type_b": 0,
      "statement_a": "The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int \u00d7 fractional_occupancy. For CB1, k_recycle \u2248 0.02 min\u207b\u00b9, k_int \u2248 0.",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "CB1 internalization follows agonist-driven \u03b2-arrestin-dependent endocytosis; at low occupancy, the internalization flux (k_int \u00d7 occupied_receptors) remains below the constitutive recycling/synthesis ",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    }
  ],
  "independent_replications": [
    {
      "run_a": "evo_20260211_024747_pharmacology",
      "run_b": "evo_20260211_024750_neuroscience",
      "cosine": 0.6637,
      "classification": "INDEPENDENT REPLICATION",
      "type_a": 1,
      "type_b": 0,
      "statement_a": "3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (\u22642.5 mg/day) adds to tonic 2-AG without displacement, while high-dose THC (>10 mg/day) saturates CB1, reducing 2-AG access",
      "statement_b": "1:** The biphasic (inverted-U) dose-response of THC occurs because low CB1 occupancy (<20%) preferentially engages Gi/o-ERK-CREB-BDNF signaling, while high occupancy recruits \u03b2-arrestin-2, causing rec",
      "mechanism_a": "Low-dose THC occupies CB1 without competing with 2-AG, preserving tonic signaling; high-dose THC displaces 2-AG, triggering MAGL-mediated degradation.",
      "mechanism_b": "Low-dose THC produces biased signaling at CB1, sustaining Gi/o coupling to ERK/CREB without triggering \u03b2-arrestin-mediated internalization, thereby upregulating BDNF."
    },
    {
      "run_a": "evo_20260210_232904_pharmacology",
      "run_b": "evo_20260210_235609_pharmacology",
      "cosine": 0.6365,
      "classification": "INDEPENDENT REPLICATION",
      "type_a": 1,
      "type_b": 0,
      "statement_a": "(Supporting SINGULAR thread) Neuronal BDNF/TrkB signaling is potentiated by low-dose lithium via GSK-3\u03b2 inhibition and CREB activation, providing a robust compensatory pro-survival signal absent in re",
      "statement_b": "2:** Neuroprotection at low dose is mediated primarily by indirect GSK-3\u03b2 inhibition via Akt-Ser9 phosphorylation amplification, with effective EC50 ~0.2\u20130.5 mM intracellular \u2014 achievable at plasma [L",
      "mechanism_a": "Lithium-enhanced BDNF/TrkB signaling activates PI3K/Akt and ERK pathways, which converge on mTOR and Bcl-2 to suppress apoptosis and enhance autophagy, buffering against mild metabolic stress.",
      "mechanism_b": "Li\u207a inhibits PP1/PP2A-mediated dephosphorylation of Akt-phosphorylated GSK-3\u03b2-Ser9, creating a signal amplification loop where small [Li\u207a] produces disproportionate GSK-3\u03b2 suppression."
    }
  ],
  "structural_patterns": {
    "two_pathway": [
      "evo_20260210_232904_pharmacology",
      "evo_20260212_032819_pharmacology"
    ],
    "threshold_crossover": [
      "evo_20260210_232904_pharmacology",
      "evo_20260210_235609_pharmacology",
      "evo_20260211_024747_pharmacology",
      "evo_20260211_024750_neuroscience",
      "evo_20260212_032819_pharmacology"
    ],
    "dose_dependent": [
      "evo_20260210_232904_pharmacology",
      "evo_20260211_024747_pharmacology",
      "evo_20260212_032819_pharmacology"
    ]
  },
  "stats": {
    "total_claims": 65,
    "cross_matches_found": 30,
    "cross_validated_singulars": 14,
    "convergent_singulars": 3,
    "independent_replications": 2,
    "cross_promoted": 5,
    "structural_patterns_found": 3
  }
}